Current Report Filing (8-k)
07 February 2020 - 9:10AM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
February 6, 2020
iBio, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
(State or jurisdiction of incorporation
or organization)
001-35023
(Commission File Number)
26-2797813
(I.R.S. Employer Identification Number)
600 Madison Avenue, Suite 1601, New York,
NY 10022-1737
(Address of principal executive offices
(Zip Code)
Registrant's telephone number: (302) 355-0650
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Emerging growth company
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Ticker symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock
|
|
IBIO
|
|
NYSE American
|
On February 6, 2020,
iBio, Inc. (the “Company”) issued a press release announcing the postponement of its 2019 annual meeting of stockholders
(the “Annual Meeting”). The Annual Meeting was rescheduled to be held on March 5, 2020, at 9:30 a.m. local time at
The Omni Berkshire Place Hotel, 21 East 52nd Street, New York, New York 10022.
The Company decided
to postpone the Annual Meeting after becoming aware that Definitive Proxy Statement filed with the Securities and Exchange Commission
on January 23, 2020 (the “Proxy Statement”) was not timely delivered to beneficial holders of the Company’s common
stock before the originally scheduled meeting date. The Annual Meeting has been postponed to March 5, 2020 to ensure that all stockholders
receive materials required by the proxy rules under the Securities Exchange Act of 1934 and the requirements under Schedule 14A.
A copy of the press
release issued by the Company is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01.
Item 9.01
|
Financial Statements and Exhibits.
|
*Filed herewith.
Signatures
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
IBIO INC.
|
|
|
|
Date: February 6, 2020
|
By:
|
/s/ Robert B. Kay
|
|
|
Robert B. Kay
|
|
|
Executive Chairman and CEO
|
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2024 to May 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From May 2023 to May 2024